While many have their tales of triumph and woes as part of the medical device industry or pharmaceutical world, the question posed in the heading was recently covered in a Forbes post. The article, written by Dr. David Shaywitz, opens with a zinger, “Good news, early-stage biopharma companies: at least you’re not early-stage device companies.” But what exactly makes one more challenging than the other?